[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemorrhagic-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemorrhagic-stroke":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,54,83,111,150,180,205,235,265,291,315,339,361,391,419,448,475,497,525,550,577,599],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100603938","the-use-of-p4864-mw-hpc-flow-modulation-device-in-the-treatment-of-wide-necked-intracranial-aneurysms-100603938",false,"NCT07143019","The Use of p48\u002F64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms","p48\u002F64 MW HPC in Aneurysm Occlusion (PIANO): Prospective, Multicenter, Single-arm Clinical Trial to Determine Safety and Effectiveness of the Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms.","PIANO","Inclusion Criteria:\n\n1. Subject is ≥ 18 years\n2. Subject has a mRS ≤2 before the index procedure\n3. Subject has an unruptured or recanalized intracranial aneurysm (IA). The subject may also have a previous ruptured aneurysm, provided rupture of this aneurysm has occurred more than 30 days from the index procedure. The IA must have the following characteristics below:\n\n   1. Saccular or fusiform morphology\n   2. Located in the internal carotid artery and its branches\n   3. Aneurysm neck ≥4 mm or dome-to-neck ratio \\\u003C2\n   4. Parent vessel diameter ≥2.0mm and ≤5.0mm both distal and proximal to the target IA\n4. Subject or subject's legally authorized representative (LAR) has provided written informed consent and has agreed to comply with study procedures.\n\nExclusion Criteria:\n\n1. Previous flow diverter or stent within the parent vessel of the target aneurysm to be treated\n2. Any other known IA requiring treatment within 3 months post-procedure\n3. Subarachnoid hemorrhage in the past 30 days prior to the index procedure\n4. Has a true bifurcation aneurysm, defined as an aneurysm (saccular or non-saccular) located at the point of vessel bifurcation\n5. Anatomy unsuitable for endovascular procedure due to severe vessel tortuosity or stenosis, or stented ipsilateral carotid artery within 3 months prior to the index procedure\n6. Subject with a brain arteriovenous malformation (AVM) or other vascular malformation in the area of the target aneurysm\n7. Major surgery in the last 30 days, including endovascular procedures, or is planned in the next 90 days after enrollment date\n8. Unstable neurologic deficit (i.e., any worsening of clinical condition in the last 30 days)\n9. Known serious sensitivity to radiographic contrast agents that cannot be managed medically\n10. Known sensitivity to nickel, titanium metals or their alloys or any other investigational device components\n11. Irreversible bleeding disorder and\u002For signs of active bleeding at subject presentation\n12. Known renal failure with a serum creatinine \\>2.5 mg\u002Fdl (or 220 μmol\u002Fl) not on dialysis\n13. Contraindication to CT scan, MRI, or angiography\n14. Contraindication or known allergies to anticoagulants or antiplatelets (e.g. aspirin, heparin, clopidogrel, prasugrel, or ticagrelor)\n15. Known coagulopathy, or an admission International Normalized Ratio \\>3.0 without oral anticoagulation therapy, or an admission platelet count of \\\u003C100000\n16. Has acute life-threatening illness other than the neurological disease (i.e., acute kidney or heart failure) to be treated in this trial\n17. Unable to complete the required study follow-ups\n18. Evidence of active infection at the time of treatment (e.g., fever, elevated white blood cell count)\n19. Participating in another clinical trial that could affect participation or primary outcomes of this study\n20. Women currently pregnant or wish to become pregnant during the study or breast feeding.","ALL","18 Years",{"count":20,"type":21},214,"ESTIMATED","INTERVENTIONAL",[24],"NA","To determine safety and effectiveness of the p48 MW HPC and p64 MW HPC Flow Modulation Device in the treatment of wide-necked intracranial aneurysms.",[27,28,29,30,31],"Hemorrhagic Stroke","Aneurysm, Intracranial","Saccular Aneurysm","Fusiform Aneurysm","Brain Aneurysm",[33,34,35,36,37,38,39,40],"Neurovascular Intervention","phenox","Brain","Unruptured Aneurysm","Flow diversion","Flow diverter","Occlusion","Flow modulation device","RECRUITING","2026-06-22",{"date":44,"type":45},"2026-06-25","ACTUAL",{"date":47,"type":45},"2026-03-16",{"date":49,"type":21},"2032-07",{"name":51,"class":52},"phenox Inc.","INDUSTRY",21,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100641099","feasibility-of-a-remotely-delivered-step-count-intervention-in-chronic-stroke-100641099","NCT07649135","Feasibility of a Remotely Delivered Step Count Intervention in Chronic Stroke","Feasibility of Engaging Stroke Survivors in a Brief Step Count Intervention During Chronic Stroke","PA-ChatS","Inclusion Criteria:\n\n* Stroke diagnosis confirmed by imaging\n* Stroke occurred 6 or more months before study enrollment\n* Meet criteria for \"inactive\" on the International Physical Activity Questionnaire-Short Form\n* Able to identify a support person that they interact with in-person at least once per week\n* Able and willing to participate fully in the study and provide informed consent or proxy consent with participant assent\n\nExclusion Criteria:\n\n* Currently receiving care in a transitional care unit, skilled nursing facility, or other institutional care setting\n* Currently receiving outpatient neurorehabilitation services (e.g., physical therapy, occupational therapy, speech therapy)\n* Severe cognitive or communication impairments (inability to respond accurately to complete study screening questions or to provide informed consent or assent)\n* Currently pregnant or expecting to become pregnant in the next 8 weeks Comorbid neurological disorder (Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, myasthenia gravis, dementia, Alzheimer's disease, Huntington's disease, glioblastoma, spinal cord injury, cerebral palsy)\n* Comorbid cancer, currently undergoing chemotherapy or radiation treatment\n* Received inpatient treatment or was hospitalized for a psychiatric condition and\u002For alcohol or substance abuse within the past 12 months\n* Current diagnosis of a terminal illness and\u002For currently receiving hospice care\n* History of allergic reaction to adhesives that precludes the use of an adhesive necessary for adherence to activPAL measurement\n* Uses wheelchair as primary mobility aid outside of home setting\n* Inability to speak, read, or understand English\n* Concurrent participation in another rehabilitation intervention research study\n* Resides more than 50 miles outside of the Twin Cities, Minnesota metropolitan area\n* Investigator discretion for safety or adherence reasons",{"count":63,"type":21},24,[24],"The goal of this study is to explore the feasibility of a new approach to rehabilitation that focuses on step count. Participants will complete 6 telephone or Zoom-based sessions with an occupational therapist over 6 weeks and use a step count tracker during that time. They will also complete questionnaires, assessments, surveys, and physical activity measurements during study weeks 0 (baseline), 3 (mid-point), 7 (post-intervention) and 12 (follow-up).",[67,68,27],"Stroke","Ischemic Stroke",[70,71,72],"physical activity","behavior change","rehabilitation","NOT_YET_RECRUITING","2026-06-16",{"date":76,"type":45},"2026-06-18",{"date":42,"type":21},{"date":79,"type":21},"2027-01",{"name":81,"class":82},"University of Minnesota","OTHER",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100437390","goal-attainment-scaling-in-upper-limb-spasticity-treatment-100437390","NCT04975646","Goal Attainment Scaling in Upper Limb Spasticity Treatment","Goal Attainment Scaling in Upper Limb Spasticity Treatment With Botulinum Toxin and the Influence of Regular Exercise for Spastic Upper Limb on Quality of Life in Patients After Stroke","GASBTX","Inclusion Criteria:\n\n* patient's or caregiver's approval\n* ischemic or hemorrhagic stroke diagnosed using head CT\u002FMRI\n* at least one upper limb muscle spasticity (MAS ≥ 3)\n* candidate for BTX-A treatment or already given BTX-A in the past\n* patient's or caregiver's capability for goal attainment protocol cooperation (Mini Mental Examination ≥ 24 points)\n\nExclusion Criteria:\n\n* aphasic patients without caregiver's presence\n* other neurological or musculoskeletal diseases that could affect the treatment outcome",{"count":92,"type":21},70,[24],"Patients after stroke with upper limb spasticity treated with botulinum toxin-A (BTX-A) will be included in this two-part study. In the first part, goal attainment scaling and comprehensive assessment of motor functioning will be performed before BTX-A application and after two weeks. In the second part, the patients will be randomised into a test group performing prescribed regular exercise for two weeks and a control group exercising at their own discretion during the same period, whereby the patients' health-related quality of life will be assessed at the beginning and end of the two-week period.",[68,27],[72,97,98,99,100],"spasticity","botulinum toxin A","goal setting","spasticity-related quality of life","2026-06-11",{"date":103,"type":45},"2026-06-15",{"date":105,"type":45},"2021-01-03",{"date":107,"type":21},"2026-10",{"name":109,"class":82},"University Rehabilitation Institute, Republic of Slovenia",1,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":130,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":149},"100641032","effectiveness-of-best-care-practices-in-acute-stroke-in-conventional-hospitalization-best-care-ictushc-100641032","NCT07627399","Effectiveness of Best Care Practices in Acute Stroke in Conventional Hospitalization (BEST CARE ICTUS_HC)","Effectiveness of Implementing Best Care Practices in the Management of Patients With Acute Stroke in Conventional Hospitalization: A Cluster-Randomized, Open, Stepped-Wedge Controlled Trial.","BESTCAREICTUS","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Clinical diagnosis of acute ischemic or hemorrhagic stroke.\n* Admission to conventional hospitalization units (Internal Medicine) in regional hospitals without specialized Stroke Units.\n\nExclusion Criteria:\n\n* Patients admitted for a cause other than stroke who develop a stroke during their hospital stay (in-hospital stroke).\n* Patients subjected to invasive neurological procedures.\n* Patients undergoing invasive procedures, such as thrombectomy, who require transfer to a referral hospital and remain there for more than 48 hours.\n* Patients with deterioration of the level of consciousness that prevents the performance of dysphagia testing.\n* Patients that have been taken care of by Nurses and Nursing Assistants with \\>4 weeks of work experience in Stroke Units in the last 12 months",{"count":120,"type":21},700,[24],"The goal of this clinical trial is to evaluate whether a multicomponent nurse-led intervention (BEST CARE ICTUS\\_HC) can reduce stroke-related complications and improve recovery in adults (18 years and older) hospitalized with an acute ischemic or hemorrhagic stroke in hospitals without specialized Stroke Units. The main questions it aims to answer are:\n\n1. Does the implementation of the program increase the early and correct detection of swallowing difficulties (dysphagia) to prevent pneumonia?\n2. Does the program reduce the severity of attention problems (hemineglect) and improve the patients' quality of life up to 6 months after discharge?\n\nResearchers will compare patients receiving the BEST CARE ICTUS\\_HC program to patients receiving usual hospital care to see if this new approach improves patient safety and long-term functional recovery.\n\nParticipants will:\n\n* Receive either the usual hospital care for stroke or the BEST CARE ICTUS\\_HC nursing program, depending on the study phase of the hospital.\n* Be screened for swallowing problems using a standardized test before receiving any food or drink.\n* Be cared for in an adapted environment (FLECHA Project) that uses visual signs and room organization to help with orientation and safety.\n* Have their temperature, blood sugar, and blood pressure monitored under a strict specialized protocol.\n* Be contacted by phone 30 days and 6 months after leaving the hospital to answer questions about their health and quality of life.",[67,124,68,27,125,126,127,128,129],"Acute Stroke","Cerebrovascular Disorders","Deglutition Disorders","Perceptual Disorders","Unilateral Neglect","Pneumonia, Aspiration",[124,131,132,128,133,134,135,136,137,138,139],"Nursing Care","Dysphagia Screening","Multicomponent Intervention","Care Bundle","Stepped-Wedge Design","Deglutition","Quality of life","Hyperglycemia","Fever","2026-05-29",{"date":142,"type":45},"2026-06-04",{"date":144,"type":45},"2026-05-12",{"date":146,"type":21},"2028-12",{"name":148,"class":82},"University of Malaga",4,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100523345","hospital-implementation-of-a-stroke-protocol-for-emergency-evaluation-and-disposition-100523345","NCT06094478","Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","Implementation of a Stroke Protocol for Emergency Evaluation and Disposition","HI-SPEED","Inclusion Criteria:\n\n* Age \\>=18 years\n* Final diagnosis: AIS, ICH, or SAH\n\nExclusion Criteria:\n\n* Final diagnosis: TIA or stroke NOS\n* Age \\\u003C18 years\n* Comfort care measures on day 0 or 1\n* Left hospital against medical advice\n* Enrolled in clinical trial related to stroke that is competing with this study",{"count":159,"type":21},900,[24],"Most stroke patients are initially evaluated at the closest hospital but some need to be transferred to a hospital that can provide more advanced care. The \"Door-In-Door-Out\" (DIDO) process at the first hospital can take time making transferred patients no longer able to get the advanced treatments. This study will help hospitals across the US \"stand up\" new ways to evaluate stroke patients, decide who needs to be transferred, and transfer them quickly for advanced treatment.",[163,164,27],"Stroke, Acute","Ischemic Stroke, Acute",[166,167,168,169],"interhospital transfer","quality improvement","implementation science","stroke systems of care","2026-05-18",{"date":172,"type":45},"2026-05-20",{"date":174,"type":45},"2024-10-17",{"date":176,"type":21},"2028-07-31",{"name":178,"class":82},"University of Chicago",8,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":187,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":22,"phases":191,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":110},"100395297","phase-4-efficacy-and-safety-of-cerebrolysin-on-prolonged-disorders-of-consciousness-100395297","NCT04427241","Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness","Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness in Patients With Hemorrhagic Stroke: A Pilot Study","Inclusion Criteria\n\n1. Patients with hemorrhagic stroke confirmed by CT or MRI\n2. Patients who have been in disorders of consciousness for more than 4 weeks after the onset of hemorrhagic stroke\n3. Patients in a vegetative state or minimally conscious state (Coma Recovery Scale -revised: CRS-R assessment)\n4. Age: 19 to 80 years of age\n5. Patients who have voluntarily given written informed consent to participate in the study by themselves or their legal representative.\n\nExclusion Criteria\n\n1. Patients with confirmed epileptiform discharges on EEG\n2. Patients with brain parenchymal defects\n3. Patients with advanced liver, kidney, cardiac, or pulmonary disease.\n4. Chronic treatment with medications that may affect consciousness, such as antidepressants, antipsychotic drugs, nootropic drugs, and vasodilators.\n5. History of serious illness within the last two years (cancer, hematologic, renal, hepatic, or coronary artery disease, psychiatric illness, diabetes, myocardial infarction, epilepsy), no evidence of secondary damage to major organs, and well-controlled diabetes or hypertension.\n6. Alcohol or drug abuse or dependence within the last 2 years (DSM-V criteria).\n7. Significant systemic disease or unstable medical condition that may compromise compliance with the study protocol.\n8. Administration of a contraindicated drug is essential for medical purposes.\n9. Contraindications to the study drug (cerebrolysin).\n10. Participation in another therapeutic study","19 Years","120 Years",{"count":190,"type":21},12,[192],"PHASE4","Object: To determine the effect of cerebrolysin on prolonged disorders of consciousness caused by hemorrhagic stroke.\n\nParticipants: patients with prolonged disorders of consciousness due to severe traumatic brain injury\n\nIntervention: 30 ml cerebrolysin + 70 ml normal saline, days 4-17, once\u002Fday, intravenously or 100 ml normal saline, days 4-17, once\u002Fday, IV\n\nComparison: cerebrolysin group versus control group\n\nOutcome: Coma Recovery Scale-revised, FDG-PET signal",[195,27],"Disorder of Consciousness","2026-05-06",{"date":198,"type":45},"2026-05-11",{"date":200,"type":45},"2023-06-01",{"date":202,"type":21},"2026-12-31",{"name":204,"class":82},"Konkuk University Medical Center",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":212,"sex":17,"minAge":18,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":234},"100447945","correlation-between-intestinal-microecology-imbalance-and-stroke-in-young-adults-100447945","NCT05113043","Correlation Between Intestinal Microecology Imbalance and Stroke in Young Adults","Research on Correlation Between Intestinal Microecology Imbalance and the Risk and Prognosis of Stroke in Young Adults","Inclusion Criteria:\n\n* Clinical diagnosis of acute ischemic or hemorrhagic stroke\n* Admission within 12 hours\n* Aged 18-45 years\n\nExclusion Criteria:\n\n* History of neurological diseases, myocardial infarction, renal and hepatic abnormalities and metabolic diseases\n* Combined with tumors, inflammatory bowel disease and other digestive system diseases\n* Combined with serious life-threatening diseases or condition\n* Any antibiotics, probiotics or prebiotic treatment within 3 months\n* Deteriorate and die before collecting faecal samples",true,"45 Years",{"count":215,"type":21},60,"OBSERVATIONAL","The relationship between the intestinal microecology and stroke has become a research hotspot in neurology field today. Maintaining the balance of the intestinal microbiota are expected to bring new breakthroughs for prevention and treatment of stroke. In recent years, stroke in young adults has an increasing incidence and a considerable socioeconomic impact because of high disability rate and health-care costs. So there is an urgent need to explore the role and mechanism of intestinal microecology imbalance in stroke, especially in the development and prognosis of stroke in young people. This study aims to use multi-omics technologies, including microbial diversity, metagenomics and metabonomics, to reveal the characteristics of intestinal flora in young stroke patients, identify biomarkers for predicting outcome after stroke and early detection of young people at high risk of stroke, and to further explore the role of gut-brain axis in the pathogenesis of stroke.",[68,27],[220,221,222,223,224],"ischemic stroke","hemorrhagic stroke","intestinal microecology","multi-omics analysis","prognosis","2026-04-22",{"date":227,"type":45},"2026-04-23",{"date":229,"type":45},"2022-02-01",{"date":231,"type":21},"2027-12-31",{"name":233,"class":82},"Shanghai 6th People's Hospital",2,{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":253,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":263,"locationsCount":110},"100539831","phase-4-atorvastatin-pretreatment-in-cerebrovascular-events-apices-after-flow-diverter-implantation-100539831","NCT06308952","Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation","Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation: Protocol of a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion criteria:\n\n1. Aged 18 to 75 years old, male or non-pregnant female;\n2. UIA diagnosed by CTA, MRA, or DSA;\n3. Maximal aneurysmal diameter between 3 and 25mm;\n4. Understands the nature of the procedure and provision of written informed consent;\n5. Indications for FD implantation with or without adjunctive coiling;\n6. Is willing to return to the investigational site for follow-up according to our protocol.\n\nExclusion criteria:\n\nPatients will be excluded if they meet any of the following criteria:\n\n1. Contraindications to atorvastatin treatment or known allergy to atorvastatin;\n2. Pregnancy or lactation;\n3. Presence of other vascular lesions (coronary artery disease, abdominal aortic aneurysm, intracranial atherosclerotic stenosis, arteriovenous malformation, dural arteriovenous fistula, Moyamoya disease, etc.);\n4. Prolonged statin therapy (≥30 days) or prior indications for atorvastatin therapy according to the Chinese guidelines for lipid management (2023) 21;\n5. Ruptured aneurysms or target aneurysm received previous operative or endovascular treatment;\n6. Patient currently using drugs that interact with atorvastatin metabolism (including transporter inhibitors, cyclosporine, protease inhibitors, other lipid-lowering medications (such as fibrates, ezetimibe, pcsk9 inhibitor, etc.), antacids, erythromycin, cytochrome P450 enzyme, colchicine, etc.);\n7. Patients diagnosed with multiple intracranial aneurysms who require treatment for two or more intracranial aneurysms within a one-year period;\n8. The target aneurysm is non-saccular (dissecting, fusiform, pseudo, infectious, etc.)\n9. Other situations that the researcher deems unsuitable for inclusion in the study (inability to receive anti-platelet or anticoagulant medication; allergy or contraindication for the use of FD alloy, history of life-threatening allergy to contrast dye, ect).\n10. Patient was determined that intravenous general anesthesia or general anesthesia with tracheal intubation could not be tolerated.\n11. Unwilling to be followed up or likely to have poor treatment compliance at initial screening;\n12. Life expectancy less than 3 years;\n13. Severe neurological deficit that renders the patient unable to live independently (modified Rankin score ≥4);\n14. Enrollment in another trial.\n\nWithdrawal criteria\n\nIn this trial, participants who have provided written informed consent but are unable to complete the entire study for any reason will be withdrawn. These circumstances include the following:\n\n1. The participants voluntarily quit the trial for various reasons;\n2. Occurrence of serious adverse events (SAEs). The study may be terminated by the participants, principal investigators, ethics committee, sponsor, or regulatory authorities based on ethical considerations;\n3. Early termination of the process based on the investigator's judgment in order to prevent development of severe complications;\n4. Significant deviation in implementation, or the subject failed to comply with the scheduled protocol;\n5. Miss the follow-up due to changes in working\u002Fliving places, or fortuitous accident (traffic accident, bone fracture, accidental death, ect.). Thus, close follow-up should be conducted to determine their relationship with the usage of FD and experimental drug;\n6. Flawed or absence of informed consents.","75 Years",{"count":244,"type":21},354,[192],"APICES trial is an investigator-initiated, multicenter, multicenter, randomized, double-blind, placebo-controlled clinical trial that plans to enroll 396 patients with a 1-year follow-up, including a neurovascular imaging examination \\[digital subtraction angiography (DSA), CT angiography (CTA) or magnetic resonance angiography (MRA)\\] at 6 months after index treatment. It was designed in compliance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The study was approved by the Ethics Committee of Zhujiang Hospital of South Medical University (2024-KY-032-02) and registered at ClinicalTrials.gov (NCT06308952). The participants will be recruited from twelve advanced stroke centers in China.",[248,249,68,27,250,251,252],"Cerebrovascular Event","Stent Stenosis","Stent Thrombosis","Death, Brain","Endothelial Dysfunction",[254,255,256,67],"Atorvastatin","Intracranial aneurysm","Flow-diverter devices","2026-02-27",{"date":259,"type":45},"2026-03-03",{"date":261,"type":45},"2024-07-30",{"date":231,"type":21},{"name":264,"class":82},"Duan Chuanzhi",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":278,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":110},"100626310","changes-in-hemodynamic-response-following-transcranial-electrical-stimulation-in-sroke-individuals-100626310","NCT07433972","Changes in Hemodynamic Response Following Transcranial Electrical Stimulation in Sroke Individuals","Inclusion Criteria:\n\n1. Unilateral stroke individuals aged 18-80 years.\n2. A first-ever stroke.\n3. Stroke onset from at least 2 weeks-5 years.\n4. Able to walk independently with or without gait aids (modified Rankin scale (mRS) 1-3)\n5. Montreal cognitive Assessment-Thai version (MoCA-T) greater than or equal to 20 scores.\n6. Ability to read, communicate, follow and understand instructions.\n\nExclusion Criteria:\n\n1. Presence of any psychological or neurological antecedent, unstable medical conditions or condition that may increase risk of stimulation such as epilepsy, seizure, and history of brain injury\n2. Having unstable cardiovascular disease or respiratory disease, and uncontrolled chronic disease such as diabetes mellitus (DM), hypertension (HT) and chronic kidney disease (CKD)\n3. Receiving other non-invasive brain stimulation or additional intervention such as TMS, PMS or acupuncture\n4. Presence of metal implantation, intracranial shunt, cochlear implantation, or cardiac pacemakers.\n5. Presence of an opened wound, infectious wound around scalp or craniectomy with unreplaced bone flap\n6. Moderate pain (numeric pain rating score \\> 4\u002F10) in any joint of the upper or lower limb, whether paretic or non-paretic\n7. Presence of color blindness\n8. Presence of any substance use including cannabis and kratom","80 Years",{"count":215,"type":21},[24],"The present study will use transcranial electrical stimulation (tES) which are transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) combined with conventional physical therapy and cognitive-motor dualt ask gait training in sub-acute (at least 2 weeks after stroke onset) to chronic stroke (within 5 years post-stroke) to investigate changes in brain hemodynamics (oxy-hemoglobin and deoxy-hemoglobin concentration) as measured by functional near infrared spectroscopy (fNIRS). The findings may provides insights changes in combining tES with rehabilitation on improvements in brain hemodynamics in sub-acute to chronic stroke.",[27,68,276,277],"Subacute Stroke","Chronic Stroke Survivors",[67,279,280,281],"functional near-infrared spectroscopy","rehbailitation","transcranial electrical stimulation","2026-02-19",{"date":284,"type":45},"2026-02-25",{"date":286,"type":21},"2026-03-01",{"date":288,"type":21},"2026-12-30",{"name":290,"class":82},"Mahidol University",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":271,"enrollmentInfo":297,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":110},"100611102","effects-of-tes-combined-with-cmdt-gait-training-on-cognition-cortical-activity-spinal-motoneuron-excitability-and-motor-performance-in-stroke-individuals-100611102","NCT07236216","Effects of tES Combined With CMDT Gait Training on Cognition, Cortical Activity, Spinal Motoneuron Excitability and Motor Performance in Stroke Individuals","Effects of Transcranial Electrical Stimulation (tES) Combined With Cognitive-motor Dual-task Gait Training on Cortical Activity, Spinal Motoneuron Excitability, Cognition and Motor Performance in Stroke Individuals",{"count":215,"type":21},[24],"The present study will use transcranial electrical stimulation (tES) which are transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS) combined with conventional physical therapy and cognitive-motor dual task gait training in sub-acute (at least 2 weeks after stroke onset) to chronic (within 5 years post-stroke) to investigate the effect on cortical activity, spinal motoneuron excitability, cognition and motor performance. The findings may enhance the evidence to support usages of tES for improvimg cognition, motor performance as well as cortical activity and spinal motoneuron excitability in a clinical setting.",[27,68,276,301],"Chronic Stroke Patient",[303,304,305,72,306,307],"stroke","electroencephalography","event related potentials","gait training","High-definition transcranial electrical stimulation",{"date":309,"type":45},"2026-02-23",{"date":311,"type":45},"2025-12-20",{"date":313,"type":21},"2027-12-30",{"name":290,"class":82},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":330,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":110},"100620140","phase-4-efficacy-and-safety-of-methylprednisolone-after-flow-diverter-stent-implantation-in-unruptured-intracranial-aneurysms-100620140","NCT07353749","Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms","Efficacy and Safety of Methylprednisolone in Preventing Adverse Cerebrovascular Events After Flow-Diverter Stent Implantation in Patients With Unruptured Intracranial Aneurysms: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* （1）Aged ≥ 18 years; （2）Diagnosed with intracranial aneurysm (IA) via CTA, MRA, or DSA;\n\n  （3）IA size ranging from 3 to 25 mm;\n\n  （4）The patient and\u002For their authorized representative can understand the study purpose, voluntarily participate, and sign the informed consent form;\n\n  （5）Patients scheduled to receive flow diverter treatment;\n\n  （6）Patients willing to complete follow-up evaluations in accordance with the clinical study protocol.\n\nExclusion Criteria:\n\n* （1）Patients with two or more multiple aneurysms who require secondary treatment within one month; （2）Female patients who are planning to become pregnant, are pregnant, or are breastfeeding;\n\n  （3）Pre-onset modified Rankin Scale (mRS) score ≥ 2;\n\n  （4）Patients complicated with systemic infectious diseases (latent or active stage), ulcerative colitis, diverticulitis, liver cirrhosis, myasthenia gravis, or ocular herpes simplex; patients with contraindications to glucocorticoids, such as active peptic ulcer and severe fungal infection;\n\n  （5）Ruptured aneurysms, recurrent aneurysms, infectious aneurysms, dissecting aneurysms; complicated with arteriovenous malformation, dural arteriovenous fistula, spinal dural arteriovenous fistula, moyamoya disease, etc.;\n\n  （6）Patients with symptomatic cerebrovascular stenosis ≥ 70%;\n\n  （7）Patients who have had a stroke (cerebral hemorrhage, cerebral infarction) within the past 30 days;\n\n  （8）Patients scheduled to undergo other surgical\u002Finterventional procedures within 30 days;\n\n  （9）Patients with severe comorbidities unsuitable for anesthesia or surgical treatment, such as major diseases of the heart, lungs, liver, spleen, and kidneys, atrial fibrillation, brain tumors, severe active infections, disseminated intravascular coagulation, and severe psychiatric history;\n\n  （10）Patients who cannot receive antiplatelet aggregation or anticoagulant therapy;\n\n  （11）Hypersensitivity to methylprednisolone sodium succinate;\n\n  （12）Patients receiving long-term hormone therapy (≥ 1 week) due to other comorbidities before surgery;\n\n  （13）Patients taking hepatic enzyme-inducing drugs, such as barbiturates, rifampicin, rifabutin, carbamazepine, phenytoin, primidone, and aminoglutethimide; or patients taking hepatic enzyme-inhibiting drugs, such as erythromycin and ketoconazole;\n\n  （14）Patients undergoing chronic hemodialysis or with severe renal insufficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin or serum creatinine \\> 220 μmol\u002FL (2.5 mg\u002Fdl));\n\n  （15）Systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 mmHg that is uncontrollable with oral antihypertensive drugs;\n\n  （16）Blood glucose \\\u003C 2.8 mmol\u002FL or \\> 22.2 mmol\u002FL;\n\n  （17）Patients who have received a vaccine injection within the past month or have a plan for vaccination;\n\n  （18）Patients who cannot understand or are unwilling to complete follow-up evaluations in accordance with the clinical study protocol;\n\n  （19）Patients with advanced diseases with an expected life expectancy of \\\u003C 6 months;\n\n  （20）Patients currently participating in other clinical trials.",{"count":323,"type":21},864,[192],"Study Title: Testing Methylprednisolone to Prevent Strokes After a Stent Procedure for Brain Aneurysms\n\nWhat is the purpose of this study? This study aims to find out if a short course of a steroid medicine called methylprednisolone can help prevent strokes and other brain-related complications in patients who have a \"flow diverter\" stent placed to treat an unruptured brain aneurysm. The main goal is to see if this treatment reduces the combined number of new strokes (both clot-related and bleeding-related) or brain injury-related deaths within the first 30 days after the procedure.\n\nWho can participate? Adults aged 18 or older with an unruptured brain aneurysm (size 3-25mm) who are scheduled to receive a flow-diverting stent and can provide informed consent may be eligible. Key reasons someone might not be able to join include: having multiple aneurysms needing quick treatment, being pregnant or breastfeeding, having a history of recent stroke, having active infections or stomach ulcers, having severe kidney disease, having very high\u002Funcontrolled blood pressure or blood sugar, or already being on long-term steroid therapy.\n\nWhat will happen in the study?\n\nThis is a multicenter, randomized, double-blind study. This means:\n\nParticipants will be randomly assigned (like flipping a coin) to one of two groups.\n\nOne group will receive methylprednisolone. The other group will receive a placebo (an inactive substance that looks identical).\n\nNeither the participants nor their doctors will know which treatment is being given.\n\nAll participants will receive the standard care for the stent procedure and aftercare.\n\nHow long will the study last? The treatment period is short (around the time of the procedure). Participants will be closely monitored in the hospital and will have a follow-up visit around 30 days after the procedure to check their health status.\n\nWhat will be measured? The researchers will mainly track whether participants have any stroke or brain injury-related death in the first 30 days. They will also check for other complications like bleeding, infections, and changes in daily function and quality of life. Safety will be monitored throughout.\n\nHow many people will take part? The study plans to enroll approximately 864 participants across multiple hospitals.\n\nStudy Dates:\n\nThe study is expected to start enrolling patients in January 2026 and finish in August 2027.\n\nWho is organizing the study? This study is sponsored and led by Zhujiang Hospital, Southern Medical University.",[327,248,27,328,329],"Unruptured Intracranial Aneurysms","Methylprednisolone","Flow Diverter",[256,255,328,248],"2026-01-17",{"date":333,"type":45},"2026-01-20",{"date":335,"type":21},"2026-01-30",{"date":337,"type":21},"2027-09-01",{"name":264,"class":82},{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":110},"100521467","using-machine-learning-and-biomarkers-for-early-detection-of-delayed-cerebral-ischemia-100521467","NCT06069973","Using Machine Learning and Biomarkers for Early Detection of Delayed Cerebral Ischemia","Machine Learning and Biomarkers for Early Detection of Delayed Cerebral Ischemia","CIDAIBASSAH","Inclusion Criteria:\n\nPatients over the age of 18 with aneurysmal subarachnoid hemorrhage admitted to intensive care units at Sahlgrenska University hospital.\n\nExclusion Criteria:\n\n* Unable to consent,\n* Cardiac arrythmia,\n* Previous brain damage","110 Years",{"count":349,"type":21},1500,"The overall goal of this project is to determine if machine learning and analysis of neurospecific biomarkers can enable early detection of upcoming or ongoing cerebral ischaemia in patients suffering from subarachnoid haemorrhage with altered consciousness due to cerebral injury or sedation. Analyses of heart rate variability, electroencephalgraphy,nearinfrared spectroscopy, cerebral autoregulation, and brain injury specific biomarkers in blood and cerebrospinal fluid will be performed.",[68,27],"2026-01-08",{"date":354,"type":45},"2026-01-12",{"date":356,"type":45},"2024-01-01",{"date":358,"type":21},"2033-12-31",{"name":360,"class":82},"Sahlgrenska University Hospital",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":370,"conditions":371,"keywords":376,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":389,"locationsCount":110},"100610176","left-atrial-strain-and-cryptogenic-stroke-100610176","NCT07224178","Left Atrial Strain and Cryptogenic Stroke","Left Atrial Strain: A Biomarker for Cryptogenic Stroke Prevention","LAS-ESUS","Inclusion Criteria:\n\n* Adult patients (age \\> 18 years and \\\u003C 80 years) who had a complete transthoracic echocardiography (TTE) exam at the University of Pittsburgh Medical Center (UPMC) Presbyterian Echocardiography Lab with a referral diagnosis of suspected stroke.\n\n  2- Patients with an established diagnosis of stroke by stroke neurologists.\n\n  3- Patients in sinus rhythm documented at the time of referral.\n\n  4- Availability of adequate echocardiographic images for strain quantification.\n\n  5- Clinical follow-up data available for evaluation of study endpoints, including stroke recurrence, atrial fibrillation development, and mortality.\n\n  6- Patients from collaborating centers will be included with de-identified echocardiographic images and clinical data meeting the above criteria.\n\nExclusion Criteria:\n\nIncomplete or technically difficult transthoracic echocardiography (TTE) studies and studies from subjects younger than 18 years of age will be excluded. Additional exclusion criteria include:\n\n1- Pre-existing atrial fibrillation (AF): Patients with a documented history AF prior to the index echocardiography study will be excluded because it is well established that AF justifies cryptogenic stroke requiring anticoagulation.\n\n2 -Structural heart disease: Patients with significant structural abnormalities, such as moderate or severe mitral stenosis, moderate or severe mitral regurgitation, prosthetic heart valves, devices in the left atrium, atrial septal defect or patent foramen ovale will be excluded as these conditions are known causes of stroke and abnormal left atrial function.\n\n3- Coagulopathy: Patient having disease leading to hypercoagulable (thrombus formation) state will be excluded (presence of cancer, antiphospholipid antibodies, hematological diseases).\n\n4- Inadequate clinical follow-up: Patients with insufficient follow-up data or missing medical records that preclude evaluation of study endpoints (e.g., stroke recurrence, AF development) will be excluded unless death is documented.\n\n5- Poor image quality for strain analysis: Patients having echo exams with inadequate image quality that prevent reliable strain quantification will be excluded.\n\n\\-",{"count":159,"type":21},"Cryptogenic stroke is a type of stroke in which the cause of the blood clot cannot be identified, leaving many patients without a clear treatment plan and at high risk for another stroke. Current medical guidelines recommend blood-thinning medication (anticoagulation) only when atrial fibrillation (AF) -an irregular heart rhythm- can be documented. However, AF may occur silently and remain undetected. Long term implantable (placed invasively under the skin) devices may be needed to capture these episodes.\n\nAF is known to develop from disease of the left atrium, the upper chamber of the heart that receives blood from the lungs. When the left atrium does not contract normally, blood flow may slow down, increasing the risk of clot formation. Nowadays, the left atrial (LA) function can be quantified precisely using a noninvasive ultrasound technique called strain imaging.\n\nThis study aims to determine whether reduced LA function is associated with cryptogenic stroke and its recurrence even when AF is not observed. If such an association is confirmed, LA strain could serve as a new biomarker to identify patients at risk, earlier than the development of overt AF, enhance preventive measures to reduce recurrent strokes. Because echocardiographic strain imaging is safe, cost-effective, and widely available, it may become an important tool for improving care in this high-risk population.",[372,373,27,374,375],"Ischemic Stroke, Cryptogenic","Ischemic Stroke, Embolic","Embolic Stroke of Undetermined Source","Recurrent Ischemic Stroke",[303,377,378,379,380,381,382],"embolic stroke of undetermined source","speckle-tracking echocardiography","left atrial cardiomyopathy","left atrial strain","recurrent ischemic stroke","new-onset atrial fibrillation","2026-01-06",{"date":385,"type":45},"2026-01-07",{"date":387,"type":45},"2025-12-17",{"date":231,"type":21},{"name":390,"class":82},"University of Pittsburgh",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":22,"phases":400,"briefSummary":401,"conditions":402,"keywords":403,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":417,"locationsCount":4},"100616876","efficacy-of-early-task-oriented-rehabilitation-in-acute-stroke-recovery-100616876","NCT07311304","Efficacy of Early Task-Oriented Rehabilitation in Acute Stroke Recovery","A Randomized Controlled Trial on the Efficacy of Early Task-Oriented Rehabilitation in Acute Stroke Recovery Compared to Traditional Rehabilitation","Inclusion Criteria:\n\n* Acute ischemic or hemorrhagic stroke diagnosed clinically and confirmed by imaging.\n* Admission to hospital or referral to outpatient clinic within 48 hours after stroke onset.\n* Age ≥ 18 years.\n* Both sexes.\n* Medically stable and fit for rehabilitation.\n\nExclusion Criteria:\n\n* Severe stroke not suitable for rehabilitation.\n* Severe comorbidities (e.g., vital organ failure, malignancy).\n* Severe aphasia, or severe visual or auditory impairment interfering with training.\n* Severe upper limb spasticity (Modified Ashworth Scale \\> 3).\n* Cognitive dysfunction (MMSE \\\u003C 24 for educated; \\\u003C 17 for illiterate patients).\n* Stroke mimics (e.g., seizures, brain tumor, CNS infection, demyelinating diseases, hypoglycemia).\n* Pregnancy.",{"count":399,"type":21},158,[24],"Stroke is one of the leading causes of long-term disability worldwide, and early rehabilitation is considered crucial for improving functional recovery. Traditional physiotherapy mainly focuses on mobility, strength, and general exercises, while task-oriented rehabilitation emphasizes practicing meaningful, goal-directed activities related to daily life. This randomized controlled trial aims to evaluate the efficacy of early task-oriented rehabilitation compared to traditional rehabilitation in acute stroke patients. Patients admitted with ischemic or hemorrhagic stroke within 48 hours will be randomly assigned to either a task-oriented rehabilitation program or conventional physiotherapy. Interventions will be delivered 3-4 times per week, 45-60 minutes per session, during hospitalization and continued in outpatient follow-up. The primary outcome will be functional independence assessed at 3 months. Secondary outcomes will include stroke severity, quality of life, and patient-reported outcomes. The findings are expected to provide evidence for improving rehabilitation strategies in Egypt.",[67,68,27],[404,405,406,407,408,409,68,27,410],"Task-Oriented Rehabilitation","Early Rehabilitation","Stroke Recovery","Neurorehabilitation","Physical Therapy","Motor Function","Randomized Controlled Trial","2025-12-21",{"date":413,"type":45},"2025-12-30",{"date":415,"type":21},"2026-01-01",{"date":288,"type":21},{"name":418,"class":82},"Assiut University",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":22,"phases":429,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":110},"100588379","exploratory-study-on-the-potential-cross-system-effects-of-bci-fes-hand-therapy-on-dysphagia-and-aphasia-in-chronic-stroke-patients-100588379","NCT06940635","Exploratory Study on the Potential Cross-System Effects of BCI-FES Hand Therapy on Dysphagia and Aphasia in Chronic Stroke Patients","Cross-Stroke Therapy Effects With BCI and FES Stimulation: A Pilot Study","c-STEPS","Inclusion Criteria:\n\n* Age: Participants must be aged 18 years or older.\n* Post-Stroke Phase: Participants must be within the chronic post-stroke phase (time since ischemic or haemorrhagic stroke greater than 3 months).\n* Motor Impairment: Participants must exhibit disabling left or right residual arm paresis (\"left\u002Fright arm motor drift\" part of the NIHSS score ≥1).\n* Speech\u002FSwallowing Impairment: Participants must have:\n\n  * Aphasia (AAT-Skala zum Kommunikationsverhalten score ≤3), and\u002For\n  * Dysphagia (MUCCS-N score ≥2).\n* Stable Neurological Status: No relevant changes in neurological status in the past 4 weeks (self-reported).\n* Motor Function: Participants must be able to raise at least 1 block similar to the ones in Box-and-Block-Test.\n* Cognitive Understanding: Participants must be able to understand basic spoken instructions.\n* Sitting Tolerance: Participants must be able to maintain a sitting position for at least 60 minutes.\n* Willingness to Participate: Participants must be willing to participate in the study and able to understand and sign the informed consent.\n\nExclusion Criteria:\n\n* Cognitive Impairments: Cognitive impairments that, in the investigator's judgment, could limit understanding of task instructions.\n* Stroke Location: Participants with a brainstem and\u002For cerebellar stroke.\n* Previous Stroke: Participants with a previous disabling stroke.\n* Hemi-Neglect: Pronounced hemi-neglect at the last documented therapy visit that limits compliance with treatment intervention (investigator's judgment).\n* Anosognosia: Pronounced anosognosia at the last documented therapy visit that limits compliance with treatment intervention (investigator's judgment).\n* Spasticity: Severe spasticity in the affected limb, resulting in complete rigidity in flexion or extension.\n* Seizure Disorders: Participants with uncontrolled epilepsy (investigator's judgement) or epileptic seizure within the last month.\n* Intracranial Pressure: Known ongoing elevated intracranial pressure.\n* Implanted Medical Devices: Participants with implanted medical devices with contraindication for FES such as pacemakers.\n* Metallic Fragments: Participants with implanted metallic fragments in the extremity planned for FES that would limit the use of functional electrical stimulation (FES).\n* Unhealed Injuries: Unrecovered fractures or skin\u002Ftissue lesions in the FES stimulated extremity.\n* Joint Issues: Ossification, contraction, or stiffness of the wrist joint in the FES stimulated extremity that would limit treatment.\n* Botulinum Toxin: Participants who received botulinum-toxin treatment within 6 weeks prior to study inclusion and\u002For for whom botulinum-toxin treatment is planned during the study duration.\n* Co-morbidities: The following conditions will exclude participation:\n\n  * Chronic Obstructive Pulmonary Disease (Stage IV).\n  * Cardiac insufficiency (NYHA Stage IV).\n  * Severe acute infections.\n  * Significant circulatory disturbances in the stimulated extremity.\n  * Sensory disorders that significantly impair the patient's ability to feel pain or react to unsuitable proprioceptive stimuli.\n  * Any other general medical conditions that, in the investigator's judgment, limit the safety or performance of study procedures (investigator's judgement).\n* Electrical Stimulation Intolerance: Known inability to tolerate cutaneous electrical stimulation.",{"count":428,"type":21},10,[24],"The goal of this neurorehabilitation explorative study is to investigate how a closed-loop Brain-Computer Interface Functional Electrical Stimulation (BCI-FES) therapy, used within the intended purpose for hand rehabilitation, may impact swallowing difficulties (dysphagia) and language disorders (aphasia) in post-stroke patients.",[432,27],"Ischaemic Stroke",[434,435,436,437,438],"neurorehabilitation","BCI-FES","chronic stroke","aphasia","dysphagia","2025-11-25",{"date":441,"type":45},"2025-11-26",{"date":443,"type":45},"2025-06-04",{"date":445,"type":21},"2026-06-30",{"name":447,"class":82},"VASCage GmbH",{"id":449,"slug":450,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":455,"targetDuration":457,"studyType":216,"phases":4,"briefSummary":458,"conditions":459,"keywords":465,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":110},"100310212","stroke-recovery-initiative---registry-for-stroke-research-studies-100310212","NCT03318432","Stroke Recovery Initiative - Registry for Stroke Research Studies","Stroke Recovery Initiative - Stroke Registry","* 18 years of age or older\n* Have suffered a stroke\n* Have ongoing symptoms as a result of the stroke",{"count":456,"type":21},60000,"5 Years","The Stroke Recovery Initiative is a nation-wide participant recruitment registry that connects people who have had a stroke with researchers who are working to develop new approaches to improve recovery after stroke.",[67,124,68,27,460,461,462,463,464],"Subarachnoid Hemorrhage","Cerebral Ischemia","Cerebral Infarction","Cerebral Stroke","Cerebral Vascular Accident",[67,124,68,27,461,462,463,464,406],"2025-09-26",{"date":468,"type":45},"2025-10-02",{"date":470,"type":45},"2013-02-09",{"date":472,"type":21},"2028-09",{"name":474,"class":82},"University of California, San Francisco",{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":17,"minAge":482,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":149},"100592875","diagnostic-performance-study-of-the-emvision-emu-brain-scanner-in-the-detection-of-intracranial-hemorrhage-in-suspected-stroke-patients-100592875","NCT06999122","Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients","Multi-Center, Prospective, Consecutive, Paired Diagnosis, Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients","Inclusion Criteria:\n\n1. Adults ≥22 years of age\n2. Presenting to hospital with acute neurological deficit suspected to be stroke and within 12 hours of symptom onset\n3. The use of the EMVision emu™ Brain Scanner will not delay the treatment of the patient\n4. CT or MRI brain imaging following clinical evaluation in Emergency Department per standard of care\n5. Head size deemed suitable for scanning with the EMVision emu™ Brain Scanner -\n\nExclusion Criteria:\n\n1. Has received treatment for current (suspected) stroke event prior to initial CT\u002FMRI scan OR EMVision emu™ Brain Scanner scan (such as thrombolysis)\n2. Contraindication to neuroimaging, such as a contrast allergy or other condition that prohibits CT, MRI and\u002For angiography\n3. Presence of any implanted electro-stimulating devices in the head and neck\n4. Presence of any metallic implants in the cranial vault or surrounding bones\u002Ftissue (Note that metallic objects distant from the scan area, such as dental implants, nasal piercing etc., are acceptable)\n5. Presence of an intracranial pressure monitor or any other similar sensor that may compromise the placement of the investigational device\n6. Inability to wear the investigational device (skin lesions on scalp, obvious recent blunt or penetrating injury to head, previous intracranial surgeries, neck injury etc.)\n7. Unable to lie still for the duration of the scan\n8. Pregnant or breastfeeding\n9. Any other condition or symptoms preventing the participant from entering the study, according to the investigator´s judgment -","22 Years",{"count":484,"type":21},300,"The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available.\n\nEMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.",[67,27],"2025-06-12",{"date":489,"type":45},"2025-06-13",{"date":491,"type":45},"2025-03-26",{"date":493,"type":21},"2026-11-28",{"name":495,"class":496},"EMVision Medical Devices Ltd","NETWORK",{"id":498,"slug":499,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":271,"enrollmentInfo":505,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":508,"conditions":509,"keywords":512,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":4},"100585215","phase-4-safety-and-feasibility-of-using-cerebrolysin-in-the-treatment-of-primary-intracerebral-hemorrhage---a-prospective-randomized-open-blinded-end-point-trial-100585215","NCT06899464","Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial","Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage","CLINCH","Inclusion Criteria:\n\n* Age 18-80 years\n* NIHSS ≥8 at randomization\n* Stroke onset \\\u003C6h\n* Pre-randomization head CT demonstrating an acute, primary lobar ICH\n* ICH volume 30 to 80 mL\n* Glasgow Coma Score (GCS) 5 to 12\n* Pre-stroke independence (modified Rankin Score 0 to 2)\n* Ability to provide informed consent\n* No history of prior stroke\n\nExclusion Criteria:\n\n* Hemorrhage caused by head trauma\n* Medical history or neuroimaging findings suggestive of ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, Moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct\n* Bilateral fixed dilated pupils\n* Extensor motor posturing\n* Intraventricular extension of the hemorrhage is visually estimated to involve \\>50% of either of the lateral ventricles\n* Primary Thalamic and basal ganglia ICH\n* Infratentorial intraparenchymal hemorrhage including midbrain, pontine, or cerebellar\n* Current use of low molecular weight heparins in therapeutic dose\n* Evidence of active bleeding\n* Uncorrected coagulopathy or known clotting disorder\n* Platelet count \\\u003C 75,000, International Normalized Ratio (INR) \\> 1.4 after correction\n* End stage renal disease\n* Patients with a mechanical heart valve\n* End-stage liver disease\n* Epilepsy with grand mal seizures\n* History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements\n* Positive urine or serum pregnancy test in female subjects without documented history of surgical sterilization or post-menopausal\n* Known life-expectancy of less than 6 months\n* No reasonable expectation of recovery, Do-Not-Resuscitate (DNR), or comfort measures only prior to randomization\n* Participation in a concurrent interventional medical investigation or clinical trial\n* Inability or unwillingness of subject or legal guardian\u002Frepresentative to give written informed consent\n* Any condition that would represent a contraindication for cerebrolysin administration",{"count":506,"type":21},30,[192],"This study is designed to determine the safety and feasibility of using Cerebrolysin in treating primary intracerebral hemorrhage (ICH).\n\nThis is a multicenter, prospective, randomized, open-label, blinded end-point, phase IV parallel group study done in specialized stroke treatment centers in Poland. The study objective is to evaluate if a 14-day cerebrolysin treatment initiated within 6 hours of onset of primary lobar hemorrhage in addition to the standard of care that includes early intensive rehabilitation is safe and feasible, affects hematoma growth and improves the outcome.\n\nThis study is designed to assess the early effect of using Cerebrolysin in patients after ICH, therefore 3 months of follow-up has been chosen. Patients will receive 50 ml of Cerebrolysin once daily until day 14. Subjects will be evaluated on Day 1 (baseline), Day 2, Day 7, Day 30 and Day 90.\n\nEnrollment to the study is expected to reach 30 subjects in 12 months. The study should be completed within 15 months (the end of study).\n\nThe primary outcome measure will be change from baseline in functional independence (mRS 0-2) at Day 90 following stroke onset. The safety outcome will be the number of serious adverse events until Day 30.",[510,511,27,67],"Intracerebral Hemorrhage","Hemorrhagic Stroke, Intracerebral",[513,514,515],"Cerebrolysin in stroke","neuroprotection in stroke","Cerebrolysin in hemorrhagic stroke","2025-03-21",{"date":518,"type":45},"2025-03-28",{"date":520,"type":21},"2025-10-01",{"date":522,"type":21},"2027-04-01",{"name":524,"class":82},"Cardinal Stefan Wyszynski University",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":149},"100501973","point-of-care-low-field-mri-in-acute-stroke-100501973","NCT05816213","Point-of-care Low-field MRI in Acute Stroke","Point-of-care Low-field Magnetic Resonance Imaging in Acute Stroke (POCS) Study","POCS","Inclusion Criteria:\n\n1. symptoms suggestive of acute stroke (acute onset of a focal neurological deficit which can be referred to the involvement of a specific CNS region);\n2. stroke onset \\\u003C24 h since when the patient was last known healthy;\n3. written informed consent provided by the patient himself or by proxy (for unconscious patients, cognitively impaired or aphasic).\n\nExclusion Criteria:\n\n1. symptoms not indicative of acute stroke (e.g. syncope, tonic or clonic activity, dizziness or wooziness alone, confusion and amnesia alone, subacute or chronic development of a focal neurological deficit);\n2. inability to undergo LF-MRI due to critically impaired vital functions (e.g. hemodynamically unstable patients, need of immediate life-saving maneuvers);\n3. implanted ferromagnetic devices potentially interfering with LF-MRI (e.g. cochlear implants);\n4. impossibility to achieve written informed consent.",{"count":484,"type":21},"Consecutive patients accessing the emergency department with suspected stroke dispatch will be recruited at 3 study units: 1) ASL Abruzzo 1, hospitals of L'Aquila and Avezzano; 2) ASL Abruzzo 2, hospital of Chieti; 3) IRCCS Humanitas Research Hospital of Milan. Anonymized clinical and low-field (LF) MRI data as well as conventional neuroimaging data will be independently assessed by external units (Università Politecnica delle Marche and Policlinico di Messina, respectively). Both units will independently adjudicate the best treatment option, while the latter will also provide historical MRI data of stroke patients to develop artificial intelligence algorithms facilitating LF-MRI images interpretation (Libera Università di Bolzano). Agreement with conventional neuroimaging will be evaluated at different time points (hyperacute, acute -24 h, subacute -72 h, discharge, chronic -4 weeks). Further investigations will include feasibility study to develop an ambulance (mobile stroke unit) equipped with LF-MRI and cost-effectiveness analysis of LF-MRI. This trial will provide necessary data to validate the use of LF-MRI in the acute stroke care.",[67,68,27,536],"Magnetic Resonance Imaging",[67,538,539,540],"Diagnosis","Low-field MRI","Stroke treatment","2024-12-04",{"date":543,"type":45},"2024-12-09",{"date":545,"type":21},"2025-02-01",{"date":547,"type":21},"2026-11-01",{"name":549,"class":82},"University of L'Aquila",{"id":551,"slug":552,"hasResults":11,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":558,"targetDuration":4,"studyType":22,"phases":560,"briefSummary":561,"conditions":562,"keywords":565,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":110},"100544894","phase-4-multiple-electrolytes-injection-ii-and-normal-saline-on-hyperchloremia-in-severe-hemorrhagic-stroke-100544894","NCT06374823","Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke","The Impact of Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke Patients: A Prospective, Multicenter, Open-label, Randomized Controlled Study","MERIT","Inclusion Criteria:\n\n* Patients with a diagnosis of hemorrhagic stroke (cerebral hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage confirmed by CT or MRI, except for subdural or extradural hemorrhage caused by tramma)\n* Patients requiring fluid therapy\n* Patients over 18 years old\n\nExclusion Criteria:\n\n* Hemorrhage onset more than 72hours\n* Preexisting hyperchloremia(blood chloride \\> 110mmol\u002FL)\n* Presence of hypothalamic disease or cerebral salt wasting syndrome\n* Patients who can eat by themselves\n* Patients receiving routine RRT\n* Patients with known allergic or adverse reactions to the liquid used\n* Patients with organ failure (such as heart failure, renal failure, liver failure) or end-stage disease\n* Patients with autoimmune diseases, inflammatory diseases, metabolic diseases and blood diseases\n* Patients with serious heart disease or arrhythmia\n* Patients who are expected to have difficulty complying with the study plan or collecting data completely\n* Pregnant or lactating women\n* No informed consent was signed\n* Patients participating in other clinical trials\n* Other conditions deemed by the investigator to be ineligible for participation in the study",{"count":559,"type":21},342,[192],"Normal saline (0.9% sodium chloride), a classical crystalloid solution, is widely used to maintain fluid balance, volume resuscitation and dilute drugs during clinical practice. However, the chloride concentration of normal saline (154mmol\u002FL) is much higher than human plasma, and a large amount of infusion may lead to iatrogenic hyperchloremia in ICU patients. In contrast, the concentrations of Multiple electrolytes II is more similar to those of plasma and is considered to be a better fluid choice than normal saline.",[563,564,27],"Critical Care","Hyperchloremia",[566,567],"Saline","Crystalloid Solution","2024-04-16",{"date":570,"type":45},"2024-04-19",{"date":572,"type":21},"2024-05",{"date":574,"type":21},"2026-12",{"name":576,"class":82},"Capital Medical University",{"id":578,"slug":579,"hasResults":11,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":585,"enrollmentInfo":586,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":588,"conditions":589,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":4},"100518142","cohort-of-neurovascular-diseases-treated-in-the-acute-phase-and-followed-at-lariboisire-100518142","NCT06026696","Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière","Cohorte de Maladies Neurovasculaires Prises en Charge à la Phase aiguë et Suivies à Lariboisière","NERVAL","Inclusion Criteria:\n\n1. Adult patients ≥18 years\n2. Patients admitted to the Neurovascular Intensive Care Unit with acute cerebrovascular disease OR Patients managed for acute cerebrovascular pathology with or without stroke by the Lariboisière neurology team.\n3. No opposition from the patient to the research and for patients under guardianship or guardianship or lack of capacity to object (severe impairment of cognitive functions, dementia, etc.), no opposition from the legal representative.\n\nExclusion Criteria:\n\n1. Patient refusing to take part in the study or refusal by the legal representative in the case of patients under guardianship or curatorship\n2. Patient suffering from a rare neurovascular disease and being followed at the \"Centre de référence des maladies vasculaires rares du cerveau et de l'oeil\" (CERVCO)","100 Years",{"count":587,"type":21},5000,"Neurovascular diseases can cause ischaemic or haemorrhagic strokes. While the most common, such as atherosclerosis are widely studied, others are less well known, such as arterial dissections or cerebral angiopathies. What's more, most studies are limited to a few years' follow-up and the longer-term evolution of patients is less well assessed. Patient follow-up data available in routine practice and specific enrollment through the headache emergencies of the Lariboisière neurovascular intensive care unit (USINV) could provide a particularly rich resource.",[68,27],"2023-09-04",{"date":592,"type":45},"2023-09-07",{"date":594,"type":21},"2023-09",{"date":596,"type":21},"2038-09",{"name":598,"class":82},"Assistance Publique - Hôpitaux de Paris",{"id":600,"slug":601,"hasResults":11,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":11,"sex":17,"minAge":607,"maxAge":4,"enrollmentInfo":608,"targetDuration":610,"studyType":216,"phases":4,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":624,"locationsCount":110},"100278144","population-based-brest-stroke-registry-100278144","NCT02900521","Population-based Brest Stroke Registry","The Brest Registry of Stroke","BREST","Inclusion Criteria:\n\n* Diagnostic validated for one of the following pathologies:\n* Ischemic stroke,\n* Non-traumatic intracranial hematoma\n* Cerebral venous thrombosis Diagnostic after December 31, 2007 Age \\> 15 years on the date of the diagnostic Patient domiciled at the time of the diagnostic in one of the 79 communes defined beforehand\n\nExclusion Criteria:\n\n* Age ≤ 15 years\n* Validated diagnosis (see below, § 4.2.2) of aneurysmal subarachnoid hemorrhage cerebrovascular\n* Diagnosis made before 1 January 2008\n* Unconfirmed diagnosis\n* Patient domiciled outside the previously defined area of residence","15 Years",{"count":609,"type":21},15000,"10 Years","The registry is the main objective exhaustive list of cases validated stroke brain on a geographical area defined to calculate an incidence.",[613,614,67,615,616,68,27,125,617],"Cerebral (CVAs)","Ischemic Cerebrovascular Accident","Brain Ischemia","Brain Hemorrhage","Transient Ischemic Attack (TIA)","2023-05-25",{"date":620,"type":45},"2023-05-26",{"date":622,"type":45},"2008-01",{"date":574,"type":21},{"name":625,"class":82},"University Hospital, Brest"]